Research programme: calpain inhibitors - Teva Pharmaceutical Industries
Latest Information Update: 27 Oct 2011
At a glance
- Originator Cephalon
- Mechanism of Action Calpain inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 26 Mar 2007 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 15 Dec 2003 No development reported - Preclinical for Stroke in USA (unspecified route)
- 04 Jun 2002 This programme is still in active development